The product contains bimatoprost, the active ingredient in the Irvine, Calif. Allergan said it hopes to launch the eyelash drug next summer pending approval of a Food and Drug Administration application to be filed before the end of September. Bimatoprost's path to the cosmetic market so far parallels the one taken by Botox. read more